Although it has been reported that CSNK2B-related epilepsy outcomes are highly variable, we believe that the occurrence of a biphasic pattern of epilepsy and pharmacoresistant epilepsy in patients with CSNK2B variants is severely underestimated because the diagnosed age and last follow-up time of most patients are usually infants. The gene discussed is CSNK2B; the disease is epilepsy.